REVEX (nalmefene hydrochloride injection)
REVEX (nalmefene hydrochloride injection), an opioid antagonist, is a 6-methylene analogue of naltrexone.
REVEX is indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids.
REVEX is indicated in the management of known or suspected opioid overdose.
Published Studies Related to Revex (Nalmefene)
Nalmefene: a review of its use in the treatment of alcohol dependence. 
The opioid system modulator nalmefene (Selincro®) is approved in the EU for
as-needed use to reduce alcohol consumption in alcohol-dependent adults with a
high drinking risk level. This article reviews the efficacy and tolerability of
as-needed oral nalmefene in the treatment of alcohol dependence, as well as
summarizing its pharmacological properties.
A randomized, double-blind, vehicle-controlled crossover study to determine the anti-pruritic efficacy, safety and local dermal tolerability of a topical formulation (srd174 cream) of the long-acting opiod antagonist nalmefene in subjects with atopic dermatitis. [2011.08]
OBJECTIVE: To investigate the efficacy, safety and tolerability of topical nalmefene (SRD174), a long acting opioid antagonist for the management of pruritus associated with atopic dermatitis (AD)... CONCLUSIONS: SRD174 cream did not demonstrate efficacy in the treatment of pruritus associated with atopic dermatitis raising questions on the role of peripheral opioid receptors as a target for the treatment of pruritus in this population.
A randomized, double-blind, vehicle-controlled crossover study to determine the
anti-pruritic efficacy, safety and local dermal tolerability of a topical
formulation (srd174 cream) of the long-acting opiod antagonist nalmefene in
subjects with atopic dermatitis. 
pruritus associated with atopic dermatitis (AD)... CONCLUSIONS: SRD174 cream did not demonstrate efficacy in the treatment of
Nalmefene in the treatment of pathological gambling: multicentre, double-blind,
placebo-controlled study. 
Pathological gambling is a disabling disorder experienced by about 1% of adults. We randomised 233 participants (41.6% women) 1:1:1 to nalmefene (20 or 40 mg) or
Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. [2008.07]
BACKGROUND: Recent studies examining the moderating effects of polymorphic variation in opioid receptor genes have yielded conflicting results. We examined opioid receptor gene polymorphisms as moderators of the therapeutic effects of the opioid antagonist nalmefene... CONCLUSIONS: Our finding that the therapeutic effects of targeted nalmefene were not moderated by polymorphic variation in opioid receptor genes is consistent with two recent reports showing that variation in opioid receptor genes does not moderate the response to naltrexone. However, these findings contrast with those from two other studies, in which the Asn40Asp polymorphism in OPRM1 moderated the naltrexone treatment response. Additional research is needed to clarify the role of variation in opioid receptor genes on the response to opioid antagonist treatment of alcoholism.
Clinical Trials Related to Revex (Nalmefene)
Single-dose of Nalmefene to Modulate Neural Alcohol Cue Reactivity [Not yet recruiting]
The aim of this study is to use functional Magnetic Resonance Imaging (fMRI) to measure
neural reactivity to alcohol-related and emotional cues in alcohol dependent subjects
following a single dose of the opioid receptor modulator nalmefene. The study will be done
in a cross over design with nalmefene versus placebo.
Nalmefene Smoking Cessation Study [Completed]
Effects of Nalmefene After Single Dose on the Blood Oxygen Level Dependent (BOLD) fMRI Signal in the Ventral Striatum to Reward Responding in the Monetary Incentive Delay Task (MIDT), in Non-treatment Seeking Subjects With Alcohol Dependence Following Alcohol Challenge [Completed]
Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment and in Healthy Subjects [Completed]
To investigate if renal impairment will have an impact on the pharmacokinetics of nalmefene
Nalmefene Gambling Study: Study of Nalmefene HCl in the Treatment of Pathological Gambling [Completed]